CLARITY PHARMACEUTICALS LTD |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 4.14 AUD | +5.34% |
|
+6.15% | +117.89% |
| 04-24 | Clarity Pharmaceuticals Completes AU$10.8 Million Retail Entitlement Offer | MT |
| 04-04 | Clarity Pharmaceuticals Signs Supply Agreement with NorthStar Medical Radioisotopes | MT |
Valuation
| Fiscal Period: Junio | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|
| Capitalization 1 | 131.5 | 182.5 | 1,287 | - | - |
| Enterprise Value (EV) 1 | 76.21 | 117.4 | 1,156 | 1,198 | 1,164 |
| P/E ratio | -5.31 x | -7.37 x | -33.5 x | -25.8 x | 221 x |
| Yield | - | - | - | - | - |
| Capitalization / Revenue | 20.1 x | - | - | - | 19.5 x |
| EV / Revenue | 11.6 x | - | - | - | 17.7 x |
| EV / EBITDA | -3.22 x | -4.81 x | -30.2 x | -23.7 x | 53 x |
| EV / FCF | -5.63 x | -4.26 x | -34.1 x | -24.3 x | 27.6 x |
| FCF Yield | -17.7% | -23.5% | -2.93% | -4.12% | 3.62% |
| Price to Book | 1.37 x | 2.64 x | 8 x | 12.3 x | 10.4 x |
| Nbr of stocks (in thousands) | 257,939 | 260,663 | 310,879 | - | - |
| Reference price 2 | 0.5100 | 0.7000 | 4.140 | 4.140 | 4.140 |
| Announcement Date | 24/08/22 | 24/08/23 | - | - | - |
1AUD in Million2AUD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: Junio | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|
| Net sales 1 | - | 6.554 | - | - | - | 65.9 |
| EBITDA 1 | - | -23.69 | -24.4 | -38.27 | -50.63 | 21.97 |
| EBIT 1 | - | -23.74 | -24.5 | -38.38 | -50.73 | 21.23 |
| Operating Margin | - | -362.17% | - | - | - | 32.21% |
| Earnings before Tax (EBT) 1 | - | -23.74 | -24.5 | -40.13 | -48.79 | 22.59 |
| Net income 1 | -10.22 | -23.75 | -24.6 | -37.45 | -48.82 | 10.46 |
| Net margin | - | -362.44% | - | - | - | 15.87% |
| EPS 2 | -0.0580 | -0.0960 | -0.0950 | -0.1237 | -0.1605 | 0.0187 |
| Free Cash Flow 1 | - | -13.53 | -27.55 | -33.9 | -49.3 | 42.15 |
| FCF margin | - | -206.39% | - | - | - | 63.96% |
| FCF Conversion (EBITDA) | - | - | - | - | - | 191.89% |
| FCF Conversion (Net income) | - | - | - | - | - | 403.05% |
| Dividend per Share 2 | - | - | - | - | - | - |
| Announcement Date | 25/08/21 | 24/08/22 | 24/08/23 | - | - | - |
1AUD in Million2AUD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: Junio | 2022 S1 | 2022 S2 | 2023 S1 | 2023 S2 |
|---|---|---|---|---|
| Net sales 1 | - | - | - | - |
| EBITDA 1 | -13.69 | -9.996 | -11.14 | -13.26 |
| EBIT 1 | -13.71 | -10.03 | -11.18 | -13.31 |
| Operating Margin | - | - | - | - |
| Earnings before Tax (EBT) 1 | -13.71 | -10.03 | -11.18 | -13.31 |
| Net income 1 | -13.71 | -10.04 | -11.24 | -13.36 |
| Net margin | - | - | - | - |
| EPS 2 | -0.0570 | -0.0390 | -0.0430 | -0.0520 |
| Dividend per Share | - | - | - | - |
| Announcement Date | 28/02/22 | 24/08/22 | 28/02/23 | 24/08/23 |
1AUD in Million2AUD
Estimates
Balance Sheet Analysis
| Fiscal Period: Junio | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - |
| Net Cash position 1 | - | 55.3 | 65 | 131 | 89.2 | 124 |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - |
| Free Cash Flow 1 | - | -13.5 | -27.5 | -33.9 | -49.3 | 42.2 |
| ROE (net income / shareholders' equity) | - | -25.8% | -30.5% | -17.5% | -31.9% | 22.4% |
| ROA (Net income/ Total Assets) | - | - | - | - | - | - |
| Assets 1 | - | - | - | - | - | - |
| Book Value Per Share 2 | - | 0.3700 | 0.2700 | 0.5200 | 0.3400 | 0.4000 |
| Cash Flow per Share 2 | - | - | -0.1100 | -0.1600 | -0.1700 | -0.2000 |
| Capex 1 | - | - | 0.05 | 0.31 | 0.71 | 1.12 |
| Capex / Sales | - | - | - | - | - | 1.7% |
| Announcement Date | 25/08/21 | 24/08/22 | 24/08/23 | - | - | - |
1AUD in Million2AUD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Sell
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
4.14
AUD
Average target price
3.867
AUD
Spread / Average Target
-6.60%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +117.89% | 860M | |
| +9.42% | 115B | |
| +11.84% | 106B | |
| -14.15% | 21.84B | |
| -1.05% | 21.96B | |
| -5.29% | 19.21B | |
| -38.29% | 17.71B | |
| -4.16% | 18.08B | |
| +7.99% | 14.32B | |
| +36.24% | 12.42B |
- Stock Market
- Equities
- CU6 Stock
- Financials Clarity Pharmaceuticals Ltd
